



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01) C07K 16/46 (2006.01)

(21) International Application Number:

PCT/US2022/024368

(22) International Filing Date:

12 April 2022 (12.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/174,156 13 April 2021 (13.04.2021) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, MD 20879 (US).

(72) Inventors: **POLLIZZI, Kristen**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).
HAMMOND, Scott, A.; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).
MAZOR, Yariv; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850

(US). **PERRY, Trinity**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **PRYTS, Stacy**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **JAISWAL, Ashvin, R.**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **OGANESYAN, Vaheh**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **YANG, Chunning**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). **KUREK, Raffael**; c/o AstraZeneca UK Limited, 1 Francis Crick Ave., Cambridge Biomedical Campus, Cambridge UK CB2 0AA (GB). **CEAICOVSCAIA, Natalia**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850 (US). **FERTE, Charles**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850 (US). **CLANCY-THOMPSON, Eleanor**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).

(74) Agent: **MENSAH, Kwame N.** et al.; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).

(54) Title: BISPECIFIC ANTIBODY TARGETING PD-1 AND TIM-3

TIM-3/phosphatidylserine ELISA




FIG. 1A

(57) Abstract: The present disclosure provides methods of altering engagement between T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) and phosphatidylserine (PS) in a subject. Also provided are methods of treatment using TIM-3 binding protein wherein the TIM-3 binding domain specifically binds to the C' and DE loops of the immunoglobulin variable (IgV) domain of TIM-3.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*